Cargando…

Quality of randomized controlled trials reporting in the treatment of melasma conducted in china

BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhiwei, Chen, Yuchi, Zeng, Jingchun, Wang, Yang, Ye, Teng, Zhou, Qiaochu, Du, Xiaojing, Su, Wenting, Ding, Zhishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399216/
https://www.ncbi.nlm.nih.gov/pubmed/25872530
http://dx.doi.org/10.1186/s13063-015-0677-2
_version_ 1782366913602519040
author Chen, Zhiwei
Chen, Yuchi
Zeng, Jingchun
Wang, Yang
Ye, Teng
Zhou, Qiaochu
Du, Xiaojing
Su, Wenting
Ding, Zhishan
author_facet Chen, Zhiwei
Chen, Yuchi
Zeng, Jingchun
Wang, Yang
Ye, Teng
Zhou, Qiaochu
Du, Xiaojing
Su, Wenting
Ding, Zhishan
author_sort Chen, Zhiwei
collection PubMed
description BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their inception through to August 2014. In order to rate the report quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items (‘randomization’, ‘allocation concealment’, ‘blinding’, ‘baseline characteristics’ and ‘intention-to-treat (ITT) analysis’) were scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial. RESULTS: A total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of 4 and a maximum of 11. Some items’ information was insufficient, especially in the categories of ‘trial design’, ‘sample size’, ‘recruitment’ and ‘ancillary analyses’ with a positive rate of less than 20%. The median MIS was 1 with a minimum of 0 and a maximum of 3. Some items’ reporting was poor, especially in the categories of ‘randomization’, ‘allocation concealment and implementation’, ‘blinding’ and ‘ITT analysis’ with a positive rate of less than 10%. The mean OQS increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001). With regard to the MIS, no variable was statistically significant in the ordinal regression model. CONCLUSION: The reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of the CONSORT statement. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-0677-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4399216
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43992162015-04-17 Quality of randomized controlled trials reporting in the treatment of melasma conducted in china Chen, Zhiwei Chen, Yuchi Zeng, Jingchun Wang, Yang Ye, Teng Zhou, Qiaochu Du, Xiaojing Su, Wenting Ding, Zhishan Trials Research BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their inception through to August 2014. In order to rate the report quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items (‘randomization’, ‘allocation concealment’, ‘blinding’, ‘baseline characteristics’ and ‘intention-to-treat (ITT) analysis’) were scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial. RESULTS: A total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of 4 and a maximum of 11. Some items’ information was insufficient, especially in the categories of ‘trial design’, ‘sample size’, ‘recruitment’ and ‘ancillary analyses’ with a positive rate of less than 20%. The median MIS was 1 with a minimum of 0 and a maximum of 3. Some items’ reporting was poor, especially in the categories of ‘randomization’, ‘allocation concealment and implementation’, ‘blinding’ and ‘ITT analysis’ with a positive rate of less than 10%. The mean OQS increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001). With regard to the MIS, no variable was statistically significant in the ordinal regression model. CONCLUSION: The reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of the CONSORT statement. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-0677-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-12 /pmc/articles/PMC4399216/ /pubmed/25872530 http://dx.doi.org/10.1186/s13063-015-0677-2 Text en © Chen et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chen, Zhiwei
Chen, Yuchi
Zeng, Jingchun
Wang, Yang
Ye, Teng
Zhou, Qiaochu
Du, Xiaojing
Su, Wenting
Ding, Zhishan
Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title_full Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title_fullStr Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title_full_unstemmed Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title_short Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
title_sort quality of randomized controlled trials reporting in the treatment of melasma conducted in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399216/
https://www.ncbi.nlm.nih.gov/pubmed/25872530
http://dx.doi.org/10.1186/s13063-015-0677-2
work_keys_str_mv AT chenzhiwei qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT chenyuchi qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT zengjingchun qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT wangyang qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT yeteng qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT zhouqiaochu qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT duxiaojing qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT suwenting qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina
AT dingzhishan qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina